फेफड़ों का कैंसर (non-small cell)
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
कहाँ जाना है
इस trial के लिए 6 hospitals इन इंडिया में patients ले रहे हैं।
रजिस्ट्री समरी (तकनीकी)
The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a protein that acts as a kind of "brake" to keep the body's immune responses under control. The study is seeking for participants who: * Are confirmed to have NSCLC (Stage 3 or 4). * Have PD-L1 levels in more than 50% of the cancer cells. All participants in this study will receive pembrolizumab at the study clinic once every 6 weeks as an intravenous (IV) …
स्पॉन्सर: फाइजर
ClinicalTrials.gov पर NCT06758401
रजिस्ट्री पर आखिरी अपडेट 25 सितंबर 2026 · हमने 20 अक्टूबर 2026 को पढ़ा